At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1 enrolled
Drug / intervention
non-interventionalother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Follow Up Investigation For Patients Completing Study A1481276 To Investigate Developmental Progress 12 And 24 Months Following Completion Of Sildenafil Treatment
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Mar 1, 2013·Updated Feb 1, 2021
In Brief
An observational study evaluating non-interventional for Pulmonary Hypertension, Persistent, of the Newborn. Completed, enrolled 1 participant across 1 site.
Detailed Summary
This single center study will monitor the developmental progress of PPHN patients who received iv sildenafil in study A1481276. Two visits will be conducted, at 12 and 24 months following the end of study drug infusion.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
First PostedMar 2013
Primary CompletionDec 2013
TodayJul 2026
First PostedMar 1, 2013
Enrollment StartNov 1, 2012
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.3 years ago
Interventions
non-interventionalother
non-interventional